Primer, double-stranded DNA production device using the primer, and double-stranded DNA production method

By introducing primers with decomposed protecting groups into the nucleoside sugar part, the problems of low efficiency and high cost of DNA replication termination are solved, and efficient and inexpensive double-stranded DNA adhesion end formation is achieved, which improves the efficiency of ligation reaction and avoids enzymes Dependence on site specificity is worse.

CN114302965BActive Publication Date: 2024-11-12THE JAPAN SCI & TECH AGENCY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080054777.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-07-31
Filing Date
2020-07-31
Publication Date
2024-11-12
Estimated Expiration
2040-07-31

AI Technical Summary

Technical Problem

The prior art has low termination efficiency and high cost due to the use of protecting groups during DNA replication, and enzyme-dependent methods have problems such as poor site specificity and low ligation reaction efficiency.

Method used

A primer that introduces a decomposition protecting group into the sugar portion of nucleosides is developed, and deprotection is carried out by light irradiation or reduction treatment, and double-stranded DNA with adherent ends is generated, amplified by PCR and formed by deprotection by 3'. Double-stranded DNA at the ends are recessed for efficient ligation.

Benefits of technology

It achieves efficient termination of DNA replication and cheap production of primers, improves the adhesion end formation efficiency of double-stranded DNA, reduces the cost and time of ligation reaction, and does not require reliance on restriction enzymes, and improves the efficiency of ligation reaction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114302965B_ABST
    Figure CN114302965B_ABST
Patent Text Reader

Abstract

The present invention is a primer used for nucleic acid amplification, and has a structure shown in the following formula (1). (Here, B represents a base, R1 represents a degradable protective group, and R2 represents hydrogen or a hydroxyl group. * refers to the bond with the sugar of the adjacent nucleotide.) The present invention is also a double-stranded DNA manufacturing device, which has: a forward primer and a reverse primer having a structure shown in formula (1); a PCR device that performs multiple cycles of PCR using a template DNA as a template to generate a double-stranded DNA with a recessed 3' end; and a light irradiation device that deprotects R1 to form an adhesion end with a protruding 3' end. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a primer, an apparatus for producing double-stranded DNA using the primer, and a method for producing double-stranded DNA. Background Art

[0002] In the field of molecular biology, in order to carry out gene recombination or transformation, a vector obtained by integrating a target DNA into a host is used. Usually, when the amount of the target DNA is small, it is used after amplification by polymerase chain reaction (PCR). In PCR, a template DNA containing a target DNA sequence is used, and primers complementary thereto are used to repeatedly perform multiple cycles of thermal denaturation and annealing to amplify the template DNA.

[0003] The amplification product of the template DNA amplified by PCR is directly blunt-ended, and needs to be treated in order to bind (connect) it to a host DNA such as plasmid DNA. Usually, a restriction enzyme that cuts a specific sequence is used as such a treatment, but in this method, since the DNA that can be bound depends on the sequence of the restriction enzyme's cutting site, there is a problem of lack of versatility.

[0004] As a method that does not use restriction enzymes, there is the following technology: the 3' end and 5' end of the amplified product are used as adhesion ends (also called bonding ends, protruding ends, etc.), adhesion ends are also formed on the host side, and the two are connected to construct a vector. For example, in recent years, the Gibson assembly method, the In-Fusion method, the SLiCE method, etc. are known. In these methods, there is an identical sequence of about 15bp at the end of the double-stranded DNA fragment, and the chain on one side of the double-stranded DNA is digested using nuclease exonuclease activity to produce adhesion ends, and then connected. In addition, in the Gibson assembly method, Taq DNA ligase is used in vitro for connection, while in the In-Fusion method, the repair system in Escherichia coli is used for connection.

[0005] In these methods, since exonucleases are used as enzymes, in addition to being expensive, site specificity may be deteriorated due to reaction conditions, making it difficult to form quantitative adhesion ends, resulting in low efficiency of ligation reactions. Therefore, a seamless cloning method that does not use enzymes is sought.

[0006] Therefore, a method for modulating DNA with an adhesion end by chemical methods has been developed, and as a primer for PCR used in this method, a primer described in patent document 1 is known. The base at the 3' end of the nucleotide sequence equivalent to the non-complementary DNA part in the primer of the document is modified with a protecting group. The protecting group has the function of stopping the DNA replication performed by DNA polymerase, and can be separated from the modified base by light irradiation treatment or alkali treatment. In addition, in the document, a substituent introducing agent for introducing a protecting group (substituent) into a biological molecule is used to introduce a base protecting group into the base of the primer.

[0007] Prior art literature

[0008] Patent Literature

[0009] Patent Document 1: International Publication No. 2009 / 113709 (claim 1, claim 2, etc.). Summary of the invention

[0010] Technical problem to be solved by the invention

[0011] In Patent Document 1, although DNA replication is terminated at the protective group portion, the polymerase activity is inhibited by the protective group at the base portion, so the termination efficiency is low, and as a result, complete extension may sometimes occur. In addition, for example, there are four types of bases in DNA, namely adenine, guanine, cytosine, and thymine, but in Patent Document 1, in order to introduce a protective group into the base, it is necessary to introduce the protective group by a method corresponding to the type of base, which is time-consuming and costly in the manufacture of primers.

[0012] The object of the present invention is to provide a primer which has high termination efficiency and can be manufactured at low cost. In addition, another object of the present invention is to provide a device for manufacturing double-stranded DNA with adhesion ends using such a primer and a method for manufacturing double-stranded DNA.

[0013] Solutions to technical problems

[0014] In order to solve the above problems, the inventors have repeatedly conducted in-depth research. As a result, a primer with a degradable protective group introduced into the sugar portion of a nucleoside has been developed. In addition, it has been found that a double-stranded DNA with an adhesion end can be produced by decomposing the protective group, thereby completing the present invention.

[0015] That is, the present invention is a primer characterized in that it is a primer for amplification of a nucleic acid and has a structure represented by the following formula (1).

[0016]

[0017] (Here, B represents a base, R1 represents a degradable protective group, and R2 represents a hydrogen or hydroxyl group. * refers to the bond with the sugar of the adjacent nucleotide.)

[0018] In this case, it is preferred that the above-mentioned R1 is a photodegradable protecting group represented by the following formula (2A).

[0019]

[0020] (Here, A1 represents an alkylene group having 1 to 3 carbon atoms, which may have a branched chain having 1 to 20 carbon atoms. * indicates a bond with oxygen (O) of phosphoric acid.)

[0021] In this case, it is preferred that the above-mentioned R1 is a photodegradable protecting group represented by the following formula (4A).

[0022]

[0023] (Here, R3 represents an alkyl group having 1 to 20 carbon atoms.)

[0024] In the above case, it is more preferable that R3 is tert-butyl or adamantyl. In particular, it is more preferable that R3 is tert-butyl.

[0025] Furthermore, it is preferred that the above-mentioned R1 is a 2-nitrobenzyl group represented by the following formula (3A).

[0026]

[0027] Alternatively, it is preferred that the above R1 is a reducing agent-decomposable protecting group represented by the following formula (2B).

[0028]

[0029] (Here, A2 represents an alkylene group having 1 to 3 carbon atoms, which may have a branched chain having 1 to 20 carbon atoms. * indicates a bond with oxygen (O) of phosphoric acid.)

[0030] In this case, it is preferred that the above-mentioned R1 is a 4-nitrobenzyl group represented by the following formula (3B).

[0031]

[0032] It is preferred that two or more structures represented by the above formula (1) are continuous in sequence.

[0033] In addition, the present invention is a double-stranded DNA manufacturing device, which is a double-stranded DNA manufacturing device for using any of the primers described above to manufacture double-stranded DNA with an adhesion end, characterized in that it comprises: a forward primer, which is complementary to a portion of the sequence of the antisense strand of the template DNA serving as a template and has a structure shown in the above formula (1); a reverse primer, which is complementary to a portion of the sequence of the sense strand of the above template DNA and has a structure shown in the above formula (1); an amplification device, which performs multiple cycles of polymerase chain reaction (PCR) using the above template DNA as a template to generate a forward side extension chain extended by the above forward primer and a reverse side extension chain extended by the above reverse primer, and anneals the above forward side extension chain and the above reverse side extension chain to generate a double-stranded DNA with a 3' end recessed; and a deprotection device, which deprotects the above R1.

[0034] Moreover, the present invention is also a method for producing double-stranded DNA, which is a method for producing double-stranded DNA with an adhesion end using any of the primers described above, characterized in that it has the following steps: a preparation step, preparing a forward primer and a reverse primer, the forward primer being complementary to a portion of the sequence of the antisense strand of the template DNA serving as a template and having a structure represented by the above formula (1), and the reverse primer being complementary to a portion of the sequence of the sense strand of the template DNA and having a structure represented by the above formula (1); an amplification step, performing a plurality of cycles of polymerase chain reaction (PCR) using the template DNA as a template to generate a forward side extension strand extended by the forward primer and a reverse side extension strand extended by the reverse primer, annealing the forward side extension strand and the reverse side extension strand to generate a double-stranded DNA with a 3' end recessed; and a deprotection step, deprotecting the R1.

[0035] In this case, the above R1 is a photodegradable protecting group represented by the above formula (2A), and the deprotection step is preferably performed by deprotecting the above R1 by light irradiation.

[0036] Alternatively, the above R1 is a reducing agent-decomposable protecting group represented by the above formula (2B), and the deprotection step preferably involves deprotecting the above R1 using a reducing agent.

[0037] Furthermore, the primer preferably has two or more structures represented by the above formula (1) consecutively in its sequence.

[0038] Effects of the Invention

[0039] According to the present invention, a primer having high deprotection efficiency and can be manufactured at low cost can be provided. In addition, according to the present invention, a manufacturing device for double-stranded DNA with adhesion ends using such a primer and a manufacturing method for double-stranded DNA can also be provided. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 Schematic diagram showing a method and apparatus for producing double-stranded DNA having cohesive ends.

[0041] Figure 2 These are chromatograms of the oligonucleotide pAcGFP_Fw2 after deprotection (a) and purification (b).

[0042] Figure 3 is a diagram showing the termination of a chain extension reaction using an oligonucleotide containing a chain extension termination cage analog T* as a template.

[0043] Figure 4 is a diagram showing agarose gel electrophoresis analysis of PCR reactions.

[0044] Figure 5 is a schematic diagram of the ligation reaction of PCR fragments.

[0045] Figure 6 This is a diagram showing an experiment for preparing adhesion ends using an oligonucleotide containing T**.

[0046] Figure 7 It is a diagram showing the experimental results of the deprotection reaction of 1T using Na2S2O4.

[0047] Figure 8 It is a diagram showing the experimental results of the deprotection reaction of 2T using Na2S2O4.

[0048] Fig. 9 This is a diagram showing the outline of an experiment in which the volume of the substituent R in the phosphate modification group is further increased.

[0049] Fig.10 It is a graph showing the results of a stability test of modified oligonucleotides under thermal cycling conditions.

[0050] Fig.11 This is a graph showing the experimental results of the stability (degradation resistance) of modified primers under PCR conditions.

[0051] Fig.12 It is a diagram showing the experimental results of reverse phase HPLC analysis of the deprotection reaction of tBu type modified primer.

[0052] Fig.13 The figure shows the experimental results of the ligation reaction (Taq DNA ligase) of PCR products in a test tube.

[0053] Fig.14 It is a diagram showing the termination of a chain extension reaction using an oligonucleotide containing a chain extension termination cage analog (sequence TT, tBu type) as a template.

[0054] Fig.15It is a diagram showing the termination of a chain extension reaction using an oligonucleotide containing a chain extension termination cage analog (sequence TT, adamantyl type) as a template.

[0055] Fig.16 It is a diagram showing the termination of a chain extension reaction using an oligonucleotide containing a chain extension termination cage analog (sequences AA and TA, tBu type) as a template.

[0056] Fig.17 It is a diagram showing the termination of a chain extension reaction using an oligonucleotide containing a chain extension termination cage analog (sequences CC and GC, tBu type) as a template. DETAILED DESCRIPTION

[0057] 1. Primers

[0058] The primer of the present invention is described below. The primer of the present invention is a primer for amplification of a nucleic acid and has a structure represented by the following formula (1).

[0059]

[0060] (Here, B represents a base, R1 represents a degradable protective group, and R2 represents hydrogen or a hydroxyl group. * refers to a bond to the sugar of the adjacent nucleotide.) In addition, in the bond *, the bond on the 3' side of formula (1) is bonded to the 5' carbon of the sugar of the adjacent nucleotide on the 3' side, and the bond on the 5' side is bonded to the 3' carbon of the sugar of the adjacent nucleotide on the 5' side. In addition, R2 is hydrogen in the case of a DNA primer, and R1 is a hydroxyl group in the case of an RNA primer.

[0061] B is a base. Specifically, in the case of a DNA primer, B is selected from adenine, guanine, cytosine, and thymine. In the case of an RNA primer, B is selected from adenine, guanine, cytosine, and uracil.

[0062] The degradable protecting group of R1 refers to a protecting group (substituent) that is decomposed by any treatment. The treatment mentioned here can include: light irradiation treatment, reduction treatment, alkali treatment, acid treatment, oxidation treatment, desilylation treatment, heat treatment, esterase treatment, phosphatase treatment, etc. Since polymerases more strongly recognize the negative charge of the phosphate group of nucleic acid, it is speculated that shielding the phosphate group with a protecting group as in formula (1) can further improve the termination efficiency of the polymerase compared to introducing a protecting group into the base as in Patent Document 1.

[0063] (1) Photodegradable Protective Group

[0064] When the treatment is photoirradiation, R1 is preferably a photodegradable protecting group represented by the following formula (2A).

[0065]

[0066] (Here, A1 represents an alkylene group having 1 to 3 carbon atoms, which may have a branched chain having 1 to 3 carbon atoms or a branched chain having 1 to 20 carbon atoms. * indicates a bond with oxygen (O) of phosphoric acid.)

[0067] Examples of the alkylene group having 1 to 20 carbon atoms include a methylene group, an ethylene group, a propylene group, a tert-butyl group, a sec-butyl group, a cyclohexyl group, and an adamantyl group.

[0068] R1 is preferably a photodegradable protecting group represented by the following formula (4A).

[0069]

[0070] (Here, R3 represents an alkyl group having 1 to 20 carbon atoms.)

[0071] In particular, R3 is preferably a bulky group such as a tert-butyl group or an adamantyl group. As shown in the examples described below, the larger the volume of R3, the higher the chemical stability of the modification site and the inhibitory effect on the replication reaction. Therefore, the number of carbon atoms in R3 is 3 or more, preferably 4 or more, more preferably 7 or more, and particularly preferably 10 or more. Among the substituents described in the examples (R3 is methyl, tert-butyl, adamantyl), the order of low chemical stability is methyl < tert-butyl < adamantyl.

[0072] Examples of R1 include a 2-nitrobenzyl group represented by the following formula (3A).

[0073]

[0074] (2) Reducing agent decomposable protecting group

[0075] When the treatment is a reduction treatment, R1 is preferably a reducing agent-decomposable protecting group represented by the following formula (2B).

[0076]

[0077] (Here, A2 represents an alkylene group having 1 to 3 carbon atoms, which may have a branched chain having 1 to 20 carbon atoms. * indicates a bond with oxygen (O) of phosphoric acid.)

[0078] Examples of the alkylene group having 1 to 20 carbon atoms include a methylene group, an ethylene group, a propylene group, a tert-butyl group, a sec-butyl group, a cyclohexyl group, and an adamantyl group.

[0079] Examples of R1 include a 4-nitrobenzyl group represented by the following formula (3B).

[0080]

[0081] (3) Other degradable protective groups

[0082] As degradable protecting groups that can be removed from the modified base by alkali treatment, isobutyryl, benzoyl, acetoxymethyl, etc. can be cited. As degradable protecting groups that can be removed from the modified base by acid treatment, trityl can be cited. As degradable protecting groups that can be removed from the modified base by oxidation treatment, allyloxymethyl, dimethoxybenzyloxymethyl, trimethoxybenzyloxymethyl, etc. can be cited. As degradable protecting groups that can be removed from the modified base by desilylation treatment, tert-butyldimethoxysilyloxymethyl, tert-butyldiphenylsilyloxymethyl, etc. can be cited. As degradable protecting groups that can be removed from the modified base by heat treatment, isocyanate groups can be cited. As degradable protecting groups that can be removed from the modified base by esterase treatment, acetoxymethyl can be cited. As degradable protecting groups that can be removed from the modified base by phosphatase treatment, methyl phosphate can be cited.

[0083] Primers of the present invention are single-stranded DNA or single-stranded RNA particularly suitable for use in PCR, and are oligonucleotides or polynucleotides having a structure shown in the above formula (1) in the molecule. The number of base pairs of the primer can be appropriately set according to the sequence of the target DNA, etc., and is usually, for example, less than 20 base pairs in oligonucleotides, and more than 20 base pairs in polynucleotides. The upper limit of the number of base pairs of the polynucleotide is not particularly limited, and as a commonly used primer, for example, less than 40 base pairs are preferred. In addition, the lower limit of the number of base pairs of the oligonucleotide is not particularly limited, as long as it is a length that can be used as a primer, and as a commonly used primer, for example, more than 5 base pairs are preferred.

[0084] In the primer, compared with the structure shown in only one above-mentioned formula (1) in the sequence, it is preferred that two or more of these structures are continuous. In the case where there is only one structure of formula (1) in the sequence, in its structural part, the adhesion end cannot be formed when the DNA replication based on the DNA polymerase is not terminated. However, since the structures of two or more formulas (1) are continuous, it is more likely to terminate the replication of the DNA, and the formation efficiency of the adhesion end is improved.

[0085] 2. Primer Preparation Method

[0086] The primer of the present invention can be produced by synthesizing a modified nucleotide having the structure of the above formula (1) (hereinafter sometimes referred to as "nucleotide derivative") and linking an unmodified nucleotide thereto by a solid phase synthesis method such as the phosphoramidite method.

[0087] As an overview of the method for synthesizing a primer, first, the 5' hydroxyl group of the nucleoside is protected, and N,N-bis(diisopropylamino)chlorophosphine is reacted with the 3' hydroxyl group. Next, nitrobenzyl alcohol is reacted to introduce a degradable protecting group. After that, phosphoramidites are reacted, and unmodified nucleotides are connected by solid phase synthesis to synthesize primers. The specific method for producing the primers listed in the examples is described in detail below.

[0088] (a) Synthesis of Nucleoside Derivatives Having Reducing Agent Degradable Protective Groups (* In Formula (1), R1 is a compound of Formula (2B) and R2 is hydrogen) and Primers

[0089]

[0090] The synthesis scheme described above is followed. In the synthesis scheme described below, the numbers represent the compound numbers. First, a deoxyribonucleoside (thymidine in the following scheme) is prepared as a starting material. 4,4'-dimethoxytrityl chloride (DMTrCl) and pyridine are added thereto to bind the 4,4'-dimethoxytrityl chloride group to the 5' hydroxyl group of ribose (Compound 24). Next, N,N-bis(diisopropylamino)chlorophosphine is added to triethylamine (TEA) and tetrahydrofuran (THF) to bind the phosphoramidite to the 3' hydroxyl group of deoxyribose (Compound 25). Next, 4-nitrobenzyl alcohol is added to the reaction mixture, and then 5-(methylthio)-1H-tetrazole is added to obtain Compound 26. Thereafter, a primer is synthesized by solid phase synthesis of nucleotides in a manner to form the desired sequence using conventional methods.

[0091] 3. Method and device for producing double-stranded DNA having adhesion ends

[0092] Next, the method and apparatus for producing double-stranded DNA having cohesive ends are described. The apparatus for producing double-stranded DNA of the present invention is an apparatus for producing double-stranded DNA having cohesive ends using the primers of the present invention. In addition, the method for producing double-stranded DNA of the present invention is a method for producing double-stranded DNA having cohesive ends using template DNA containing a target DNA sequence and the primers of the present invention. Figure 1 In this embodiment, although a primer having two structures of formula (1) continuously exists is used as a primer, the same method / apparatus can be used even when there is only one structure of formula (1).

[0093] First, a primer pair for PCR amplification comprising a forward primer and a reverse primer is prepared as a reagent (preparation step). The forward primer is complementary to a portion of the sequence of the antisense strand of the template DNA and has a structure shown in formula (1). In addition, the reverse primer is complementary to a portion of the sequence of the sense strand of the template DNA and has a structure shown in formula (1).

[0094] As shown in (a) of the figure, the forward primer and the reverse primer determine the sequence in a manner that clamps the target DNA sequence to be amplified. In addition, the position of the nucleotide with a decomposable protective group of the formula (1) in the primer is designed to be complementary to the position adjacent to the 3' side of the nucleotide on the 3' end side of the 3' recessed side in the sequence of the adhesion end as the target ((c) of the figure). When the structures of more than two formulas (1) are continuous, the nucleotide on the 3' side of the nucleotide of the structure of the formula (1) is made to be the above-mentioned position. Other reagents are polymerases (Taq polymerase, etc.), buffers, dNTPs, etc. used for PCR.

[0095] Next, a PCR device (amplification equipment) is used to amplify the sequence of the template DNA (amplification process). The PCR device performs multiple cycles of polymerase chain reaction (PCR) using the template DNA as a template to generate a forward side extension chain extended by the forward primer and a reverse side extension chain extended by the reverse primer, and anneals the forward side extension chain and the reverse side extension chain to generate a double-stranded DNA with a 3' end recess (Figure (b)).

[0096] In PCR, thermal denaturation, annealing, and extension reactions are repeated to amplify the sequence of the template DNA. Although it depends on the PCR conditions, thermal denaturation is performed at about 95°C for 1 to 3 minutes, annealing is performed at the Tm ± 5°C of the primer, and extension reaction is performed for 1 to 10 minutes. There is no particular limitation on the number of PCR cycles, but it is usually about 24 to 40 cycles.

[0097] As shown in the figure, the PCR amplification product contains double-stranded DNA with a recessed 3' end. This is because when the complementary chain is synthesized using the primer as a template, the degradable protective group of formula (1) inhibits the polymerase reaction and terminates the reaction.

[0098] Then, as shown in FIG. (c), R1 is deprotected by a predetermined treatment to form an adhesion end with a 5' end protruding (deprotection step). The predetermined treatment is a treatment for deprotecting R1, and examples thereof include the above-mentioned light irradiation treatment and reduction treatment.

[0099] The deprotection mechanism is described below. As shown in the following formula, when a predetermined treatment is performed, the degradable protecting group R1 of formula (1) is detached from the phosphate of the nucleotide.

[0100]

[0101] As a light irradiation treatment, for example, there can be cited a method of irradiating light of a wavelength of 300 to 400 nm for 1 to 30 minutes using a light source device (deprotection equipment). In addition, as a reduction treatment, for example, there can be cited a method of using a reducing agent such as sodium dithionite (Na2S2O4), for example, at 70 to 80°C for 1 to 30 minutes. As a result, the degradable protecting group of the nucleoside of formula (1) of the primer is deprotected, and a double-stranded DNA with a 5' protruding end (3' recessed end) can be synthesized. For other treatments, deprotection is also performed using a device (deprotection device) for deprotecting the degradable protecting group.

[0102] In the present invention, no matter how restriction enzyme etc., all can freely design adhesion end, therefore can freely connect the DNA with desired sequence.For example, can design the sequence of target DNA and carrier, form universal adhesion end to connect in both by deprotection treatment, modulate recombinant DNA, use it for cloning or making library, build a large amount of expression systems etc.In addition, by connecting a plurality of genome sequences with adhesion end, can carry out genome overlap reaction in test tube.Or, can also introduce double-stranded DNA in cell under the state of smooth end, carry out deprotection treatment in cell, thereby carry out genome overlap reaction in cell.

[0103] Example

[0104] Hereinafter, the present invention will be specifically described based on Examples, but these Examples do not limit the purpose of the present invention. In the following Examples, unless otherwise specified, the expression "%" is a mass basis (mass percentage).

[0105] 1. Chain extension termination cage analog T*

[0106] (1) Synthesis of oligonucleotides containing the chain extension termination cage analog T*

[0107] Oligonucleotides containing the chain extension termination cage analog T* (Table 1) were synthesized using a nucleic acid automatic synthesizer (NR-2A 7MX, manufactured by Japan Techno Service Co., Ltd.) according to the phosphoramidite method. The amidite compound (chemical formula 13) of the chain extension termination cage analog T* was synthesized according to a previous report (Wu, L et al., Chem. Eur. J. 2014, 20, 12114-12122). The commercially available amidite reagent 5'-phosphate-ON reagent (manufactured by ChemGenes) was used for phosphorylation of the 5' end. The synthesized oligonucleotide was deprotected according to a conventional method and then purified by reverse phase HPLC [system: LaChrom Elite manufactured by Hitachi High-Tech Science; chromatographic column: Hydrosphere C18 (250×10 mm ID) manufactured by YMC; eluent A: 50 mM triethylammonium acetate (pH 7.0) containing 5% acetonitrile; eluent B: acetonitrile; gradient conditions, 0-60% eluent B / 20 minutes; eluent volume: 3 mL / minute; detection based on absorbance at a wavelength of 260 nm]( Figure 2 ).

[0108]

[0109] The following table shows the sequence of the synthesized oligonucleotide containing the chain extension termination cage analog T*. p indicates that the hydroxyl group at the 5' end is phosphorylated.

[0110] [Table 1]

[0111] sequence name sequence 1T 5′·ACGACTCACT*ATAGGGCGAATTCGAGCTCGGT·3′ 2T 5′·ACGACTCAT*T*ATAGGGCGAATTCGAGCTCGGT·3′ pAcGFP_Fw2 5′·pAAAGAAGGAGAT*T*AACCATGGTGAGCAAGGGCGCC·3′ pAcGFP_Rev2 5′·pAAGCAGCCGT*T*CTCACTTGTACAGCTCATCCAT·3′ pET21d_Fw2 5′·pAACCGGCTGCT*T*CCAAAGCCCGAAAGGAA·3′ pET21d_Rev2 5′·pAATCTCCTTCTT*T*AAGTTTAAACAAAATTATTTCTAGAG·3′

[0112] Figure 2 The chromatograms of the synthetic oligonucleotide pAcGFP_Fw2 after deprotection (a) and after purification (b) are shown. The peak near 14.1 minutes shown in the chromatogram before purification (a) is a peak derived from the target product. This product was fractionated and purified (b).

[0113] (2) Replication reaction using an oligonucleotide containing a chain extension termination cage analog T* as a template

[0114] Q5 (registered trademark) high-fidelity DNA polymerase, Deep Vent (registered trademark) DNA polymerase, and Phusion (registered trademark) high-fidelity DNA polymerase were purchased from New England Biolabs. Pfu DNA polymerase was purchased from Promega. The reaction solution for the enzyme reaction [containing 1 μM primer (5' fluorescein-ACCGAGCTCGAATTCGCC 3'), 1 μM template (0T, 1T or 2T, Table 1), 0.2 mM dNTPs, and 0.02 units / μL of polymerase] was prepared using the buffer provided with each enzyme under the recommended conditions. The reaction solution was heated at 95°C for 1 minute, 55°C for 30 seconds, and then at 72°C for 10, 30, or 60 minutes using an Applied Biosystems 2720 thermal cycler. 10 μL of 2× formamide loading solution was added to 10 μL of the heated reaction solution, and the mixture was heated at 90°C for 3 minutes and then analyzed by 20% modified PAGE containing 7.5 M urea ( Figure 3 The oligonucleotide chains contained in the gel after electrophoresis were detected using the ChemiDoc XRS+ imaging system based on the fluorescence from the fluorescein group modified at the 5' end of the primer chain.

[0115] Figure 3 The figure shows the termination of the chain extension reaction using an oligonucleotide containing the chain extension termination cage analog T* as a template. (a) is the sequence of the oligonucleotide used. (b) to (e) show the results of modified PAGE analysis of the chain extension reaction using a commercially available thermostable polymerase, and (f) shows the results of MALDI-TOF molecular weight analysis of the reaction using Pfu DNA polymerase and 2T as a template. The lower figure shows the analysis results of the raw material (primer) (control experiment).

[0116] Figure 3 The molecular weight analysis of the chain extension product shown in (f) was performed as follows. Under the above conditions, an enzyme reaction was performed with 2T containing PfuDNA polymerase as a template, and the reaction was heated at 95°C for 1 minute, 55°C for 30 seconds, and then 72°C for 40 minutes. 50 μL of the reaction solution was extracted with an equal amount of a mixture of TE saturated phenol and chloroform, and alcohol precipitation was performed in the presence of ammonium acetate to recover the DNA. MALDI-TOF molecular weight analysis was performed using a mass spectrometer ultrafleXtreme (Bruker Daltonics).

[0117] (3) Cloning reaction using adhesion end formation by chain extension termination

[0118] Figure 5Schematic diagram of the PCR fragment ligation reaction. The PCR fragments were ligated according to the method shown in the figure. First, the vector side fragment (5.3 kb) was modulated as follows: Figure 4 (a)). The reaction solution [0.5 μM pET21d_Fw2, 0.5 μM pET21d_Rev2, 0.8 ng / μL pET21d (Novagen), 20 mM Tris-HCl (pH 8.8, 25°C), 10 mM KCl, 10 mM (NH4)2SO4, 2 mM MgSO4, 0.1% Triton (registered trademark) X-100, 0.1 mg / mL BSA, 0.2 mM dNTPs, 0.02 U / μL Pfu DNA polymerase] was heated under the following heating conditions [(95°C, 15 sec→50°C, 30 sec→72°C, 7.5 min) / cycle×30 cycles] using an Applied Biosystems MiniAmpPlus thermal cycler.

[0119] The insert flanking fragment (0.75 kb) was modulated as follows ( Figure 4 (b)). The reaction solution [0.5 μM pAcGFP1_Fw2, 0.5 μM pAcGFP1_Rev2, 0.8 ng / μL pAcGFP1 (Takara), 20 mM Tris-HCl (pH 8.8, 25°C), 10 mM KCl, 10 mM (NH4)2SO4, 2 mM MgSO4, 0.1% Triton (registered trademark) X-100, 0.1 mg / mL BSA, 0.2 mM dNTPs, 0.02 U / μL Pfu DNA polymerase] was heated under the following heating conditions [(95°C, 15 sec→55°C, 15 sec→72°C, 1 min) / cycle × 30 cycles] using an Applied Biosystems MiniAmp Plus thermal cycler.

[0120] After the PCR reaction, 100 μL of an equal amount of a mixture of TE saturated phenol (Nacalai Tesque) and chloroform was added to 50 μL of the reaction solution, mixed vigorously, and centrifuged (14,000×g, 3 minutes) to separate the aqueous layer. Similarly, the reaction solution was extracted with 100 μL of chloroform, and then 5 μL of 3M NaOAc (pH 5.2) and 60 μL of isopropanol were added to the aqueous layer. After cooling at -30°C for 1 hour, centrifuged (20,000×g, 20 minutes) to recover DNA in the form of pellets. In order to decompose the template plasmid DNA of the PCR reaction, the two reaction products were reacted with the restriction enzyme DpnI (Toyobo) at 37°C for 1 hour (0.8 U / μL DpnI in 33 mM Tris-acetate solution (pH 7.9), 10 mM Mg(OAc)2, 66 mM KOAc, 0.5 mM dithiothreitol, and the reaction solution volume was 20 μL). Add 80 μL of water to the reaction solution, add 100 μL of an equal amount of a mixture of TE saturated phenol and chloroform, mix vigorously, and centrifuge (14,000×g, 3 minutes) to separate the aqueous layer. Similarly, extract the reaction solution with 100 μL of chloroform, add 10 μL of 3M NaOAc (pH 5.2) and 110 μL of isopropanol. After cooling at -30°C for 1 hour, centrifuge (20,000×g, 20 minutes) to recover DNA in the form of pellets. The DNA pellet was dissolved in water and analyzed by agarose gel electrophoresis (0.8% Agarose S (Wako Pure Chemical Industries, Ltd.) containing GelRed (Wako Pure Chemical Industries, Ltd.)). The concentration of the target DNA contained was calculated by comparing the band intensity with that of a DNA size marker (Quick-Load Purple 1 kbPlus DNA Ladder, New England Biolabs) [5 μL 13 ng / μL of vector DNA fragment; 50 μL 23 ng / μL of insert DNA fragment].

[0121] A 5 μL mixture of 26.5 ng of vector DNA fragment and 26.5 ng of insert fragment was added to each well of a 96-well multiwell plate and irradiated with light at about 4 mW / cm using a MAX-305 light irradiation device (Asahi Spectroscopy). 2Irradiate with light at a wavelength of 365 nm for 10 minutes. Add the solution to 25 μL of E. coli competent cell solution (NEB 5-α competent E. coli (high efficiency), New England Biolabs) for transformation. Apply it to LB agar medium containing 50 μg / mL ampicillin sodium and culture it at 37°C overnight. Select 20 colonies from the 476 colonies produced and perform colony PCR to determine whether the target insert is inserted into the vector. Analyze the PCR reaction solution by agarose gel electrophoresis, and it can be seen that 18 of the 20 clones contain the target ligation reaction product (PCR primers, 5'TAATACGACTCA CTATAGGG 3', 5'GCTAGTTATTGCTCAGCGG 3'; colony positivity rate is 90%). For the ligation reaction products of 10 clones, the bacteria containing them were liquid cultured to extract plasmid DNA. The sequence of the obtained plasmid DNA was analyzed using two primer sequences (5'GGTGATGTCGGCGATATAGG 3', 5'GCCAATCCGGATATAGTTCCT 3') using a DNA sequencer ABI PRISM 3500xL Gene Analyzer. The nucleotide sequences of the four sites from the primer DNA, the two overlapping sites, and the range between them were analyzed, and the results showed that all 10 clones contained the designed sequence, and no mutations were observed.

[0122] Figure 4 The figures show the agarose gel electrophoresis analysis of the PCR reaction. Lane 1: size marker, Lane 2: reaction solution. (a): Preparation of the vector side fragment. (b): Preparation of the insert side fragment.

[0123] 2. Analogs deprotected under reducing conditions (T**)

[0124] (1) Synthesis of deprotected analogs (T**) under reducing conditions

[0125] The synthesis scheme of the analogue deprotected under reducing conditions (reduction-deprotected analogue) is shown below. The synthesis procedure of the reduction-deprotected analogue is described below according to the synthesis scheme.

[0126]

[0127] Synthesis of 3-O-[2-(4-nitrobenzyloxy)(diisopropylamino)phosphinoalkyl]-5-O-(4,4'-dimethoxytrityl)-2-deoxy-thymidine (Compound 26)

[0128] 0.39 g (1.45 mmol) of N, N-bis (diisopropylamino) chlorophosphine was added to a mixture of 0.50 g (1.32 mmol) of compound 24 and 200 μL (1.45 mmol) of Et3N in 7 mL of THF at room temperature. The resulting mixture was stirred at room temperature for 25 minutes until the reaction was complete (compound 25). The subsequent steps were continued without purification. 0.22 g (1.45 mmol) of 4-nitrobenzyl alcohol was added to the reaction mixture, followed by 0.17 g (1.45 mmol) of 5-(methylthio)-1H-tetrazole. The reaction was completed after 20 minutes at room temperature. The reaction mixture was diluted with EtOAc and washed with saturated NaHCO3, H2O and brine. After evaporation, the mixture was purified by neutral flash silica gel chromatography (2% triethylamine in hexane / EtOAc = 2:1 to 1:1) to obtain 0.46 g (0.56 mmol) of compound 26 (42%).

[0129] (2) Synthesis of oligonucleotides

[0130] The amidite of the synthesized cleavage analog T** was made into an acetonitrile solution with a final concentration of 50 mM, and a DNA oligomer was synthesized using a DNA synthesizer according to the phosphoramidite method. Deprotection was carried out according to conventional methods, and purification was performed by reverse phase HPLC [LaChrom Elite manufactured by Hitachi High-Tech Science; chromatographic column: Hydrosphere C18 (250×10 mm) manufactured by YMC], and the structure was confirmed using MALDI-TOF / MS (Bruker). The sequence of the synthesized DNA is shown in the table below.

[0131] [Table 2]

[0132] sequence name sequence 0T 5'-ACGACTCACTATAGGGCGAATTCGAGCTCGGT-3' 1T 5'-ACGACTCACT**ATAGGGCGAATTCGAGCTCGGT-3' 2T 5'-ACGACTCACT**T**TAGGGCGAATTCGAGCTCGGT-3'

[0133] (3) Primer extension experiment

[0134] Q5 high-fidelity DNA polymerase was purchased from New England Biolabs. Pfu DNA polymerase was purchased from Promega. The reaction solution for the enzyme reaction [containing 1 μM primer (5' fluorescein-ACCGAGCTCGAATTCGCC 3'), 1 μM template (0T, 1T or 2T, Table 2), 0.2 mM dNTPs, 0.02 units / μL of polymerase] was prepared according to the recommended conditions using the buffer provided with each enzyme. Using an Applied Biosystems 2720 thermal cycler, the reaction solution was heated at 95°C for 1 minute, 55°C for 30 seconds, and then at 72°C for 10, 30 or 60 minutes. 9 μL of 2× formamide loading solution was added to the heated 9 μL reaction solution, heated at 90°C for 3 minutes, and then analyzed by 20% modified PAGE containing 7.5 M urea ( Figure 6 The oligonucleotide chains contained in the gel after electrophoresis were detected using the ChemiDoc XRS+ imaging system based on the fluorescence from the fluorescein group modified at the 5' end of the primer chain.

[0135] (4) Deprotection reaction of oligonucleotide containing 1 T** (1T)

[0136] 10 μM oligonucleotide (5'-ACGACTCACT**ATAGGGCGAATTCGAGCTCGGT-3') was dissolved in 20 mM Tris-HCl (pH 7.4), and Na2S2O4 was added to make the final concentration 1 mM. The mixture was allowed to stand at room temperature for 30 minutes. The progress of the deprotection reaction was then analyzed by reverse phase HPLC [LaChrom Elite manufactured by Hitachi High-Tech Science; column: Hydrosphere C18 (250×10 mm) manufactured by YMC] ( Figure 7 ).

[0137] (5) Deprotection reaction of oligonucleotide containing 2 T** (2T)

[0138] 10μM oligonucleotide (5'-ACGACTCACT**T**TAGGGCGAATTCGAGCTCGGT-3') was dissolved in 20mM Tris-HCl (pH7.4), and Na2S2O4 was added to make the final concentration 10mM. The mixture was left to stand at room temperature for 30 minutes. Then, the progress of the deprotection reaction was analyzed by reverse phase HPLC [LaChrom Elite manufactured by Hitachi High-Tech Science; chromatographic column: Hydrosphere C18 (250×10mm) manufactured by YMC] ( Figure 8 ).

[0139] 3. Experiments after further increasing the volume of the substituent R in the phosphate modification group

[0140] Next, when the volume of the substituent R in the phosphate modification group in the PCR terminator primer was further increased, the chemical stability of the modification site and the replication reaction inhibitory effect were evaluated. Fig. 9 2 is a diagram showing an overview of the experiment.

[0141] (1) Synthesis of amidine reagents (dT, R = Me, tBu, adamantyl)

[0142] The volume of the substituent R is further increased to improve the replication reaction inhibition effect and chemical stability.

[0143] (1-1) Synthesis of methyl dT phosphoramidite

[0144]

[0145] Reference) Chem. Eur. J. 2014, 20, 12114-12122

[0146] To a suspension of 343 mg (0.63 mg) of 5'-DMTr-thymidine in 1.7 mL of CH2Cl2 was added 300 mg (0.75 mmol) of a photoprotective amidite and 53 mg (0.75 mmol) of 1H-tetrazole under argon at 0°C, and the mixture was stirred at room temperature for 4 hours. The mixture was directly loaded onto a silica gel column (CH2Cl2 / AcOEt=3 / 1 containing 3% TEA) to obtain a crude product. The crude product was purified by silica gel column chromatography (Hex / AcOEt=3 / 1 containing 3% TEA) to obtain 309 mg of Me analog amidite (58%).

[0147] 31 P-NMR (159MHz, CDCl3): δ148.8,147.8,147.7; HR-ESI-MS (m / z)calcd.863.3392[M+Na] + , found 863.3415.

[0148] (1-2) Synthesis of adamantyl-type dT phosphoramidite

[0149]

[0150] To a solution of 258 mg (0.47 mmol) of 5'-DMTr-thymidine in 4 mL of CH2Cl2 was added 107 μL (0.61 mmol) of DIPEA and 163 mg (0.61 mmol) of bis(diisopropylamino)-Cl-phosphine at 0°C in argon, and the mixture was stirred at room temperature for 2 hours. Then, 150 mg (0.52 mmol) of 2-nitro-α-adamantylbenzyl alcohol and 50 mg (0.71 mmol) of 1H-tetrazole were added to the reaction mixture, and the mixture was stirred at room temperature for 2 hours. 50 mg (0.71 mmol) of 1H-tetrazole was added to the reaction mixture, and the mixture was stirred for another hour. After adding H2O, the reaction mixture was extracted with AcOEt, washed with brine, dried over Na2SO4, and evaporated. The crude product was purified by silica gel column chromatography (Hex / AcOEt = 1 / 1 containing 0.5% TEA) to obtain 169 mg of Ad analog subamide (37%).

[0151] 31 P-NMR (159MHz, CDCl3): δ153.1,151.9,150.2,148.1; HR-ESI-MS (m / z)calcd.983.4331[M+Na] + , found 983.4336.

[0152] (1-3) Synthesis diagram of tBu substituted analogs with four bases (A, G, C, T) using amido reagents (summary)

[0153] The following is an outline of the synthesis scheme of the amidite reagent in the case of using four bases.

[0154]

[0155] (1-4) Synthesis of Pac-dA phosphoramidite

[0156]

[0157] To a suspension of 2.0 g (2.9 mmol) of 5'-DMTr-Pac-dA in 7.5 mL of CH2Cl2 was added 2.6 g (5.8 mmol) of a photoprotective amidite and 1.0 g (8.7 mmol) of 5(methylthio)-1H-tetrazole in argon at 0°C, and the mixture was stirred at room temperature for 6 hours. The solution was poured into 200 mL of AcOEt and washed with 200 mL of water, 200 mL of a saturated sodium bicarbonate aqueous solution, and 200 mL of brine. The organic phase was dried over sodium sulfate, filtered, and purified by silica gel column chromatography (Hex / AcOEt = 2 / 1, containing 1% TEA) to obtain 1.1 g of t-Bu dT analog amidite (37%).

[0158] HR-ESI-MS(m / z)calcd.1048.4350[M+Na] + , found 1048.4437.

[0159] (1-5) Synthesis of dT Phosphoramidite

[0160]

[0161] To a suspension of 1.5 g (2.8 mmol) of 5'-DMTr-Pac-dA in 10 mL of CH2Cl2 was added 2.4 g (5.5 mmol) of a photoprotective amidite and 0.64 g (5.5 mmol) of 5-(methylthio)-1H-tetrazole in argon at 0°C, and the mixture was stirred at room temperature for 7 hours. The solution was poured into 200 mL of AcOEt and washed with 200 mL of water, 200 mL of a saturated sodium bicarbonate aqueous solution, and 200 mL of brine. The organic phase was dried over sodium sulfate, filtered, and purified by silica gel column chromatography (Hex / AcOEt = 2 / 1, containing 1% TEA) to obtain 2.0 g of t-Bu dA analog amidite (81%).

[0162] HR-ESI-MS(m / z)calcd.905.2267[M+Na] + , found 905.3978.

[0163] (1-6) Synthesis of Pac-dG Phosphoramidite

[0164]

[0165] To a suspension of 2.0 g (2.8 mmol) of 5'-DMTr-Pac-dG in 7.5 mL of CH2Cl2 was added 2.5 g (5.7 mmol) of a photoprotective amidite and 0.99 g (8.5 mmol) of 5-(methylthio)-1H-tetrazole in argon at 0°C, and the mixture was stirred at room temperature for 6 hours. The solution was poured into 200 mL of AcOEt and washed with 200 mL of water, 200 mL of a saturated sodium bicarbonate aqueous solution, and 200 mL of brine. The organic phase was dried over sodium sulfate, filtered, and purified by silica gel column chromatography (Hex / AcOEt = 2 / 1, AcOEt / MeOH containing 1% TEA = 40 / 1) to obtain 1.2 gt-Bu dG analog amidite (41%). HR-ESI-MS (m / z) calcd.1143.5678 [M+TEA] + , found 1143.5867.

[0166] (1-7) Synthesis of Ac-dC Phosphoramidite

[0167]

[0168] To a suspension of 1.8 g (3.2 mmol) of 5'-DMTr-Ac-dC in 8.0 mL of CH2Cl2 was added 2.8 g (6.3 mmol) of a photoprotective amidite and 0.73 mg (6.3 mmol) of 5(methylthio)-1H-tetrazole in argon at 0°C, and the mixture was stirred at room temperature for 6 hours. The solution was poured into 200 mL of AcOEt and washed with 200 mL of water, 200 mL of a saturated sodium bicarbonate aqueous solution, and 200 mL of brine. The organic phase was dried over sodium sulfate, filtered, and purified by silica gel column chromatography (Hex / AcOEt = 1 / 1, containing 1% TEA) to obtain 2.1 g of t-Bu dC analog amidite (74%).

[0169] HR-ESI-MS(m / z)calcd.1011.5355[M+TEA] + , found 1011.5503.

[0170] (2) Stability (degradation resistance) test of modified oligonucleotides under thermal cycling conditions (PCR conditions)

[0171] (Reaction Conditions)

[0172] A solution composed of 20 mM Tris-HCl solution, 10 mM (NH4)2SO4, 10 mM KCl, 2 mM MgSO4, pH 8.8 containing 10 μM oligonucleotide (Me1T or tBu1T) was heated under the following conditions [(95°C, 1 minute → 50°C, 30 seconds → 72°C, 3 minutes) × 30 cycles] and then analyzed by reverse phase HPLC.

[0173] (Analysis conditions)

[0174] System; LaChrom Elite manufactured by Hitachi High-Tech Science;

[0175] Chromatographic column: Hydrosphere C18 (250×4.6 mm) manufactured by YMC;

[0176] Mobile phase: Solution A: 50 mM triethylammonium acetate (TEAA, pH 7.0) containing 5% acetonitrile

[0177] Solution B: acetonitrile;

[0178] (The content of liquid B was divided into 20 parts and increased from 0% to 60% (linear gradient))

[0179] Mobile phase flow rate: 1 mL / min;

[0180] Detection wavelength: 260nm.

[0181] (result)

[0182] After thermal cycling of oligonucleotide MelT, the removal of the modified group was observed in about 50% of the substrate ( Fig.10 (d): It was confirmed that the observed peak coincided with the elution time of the oligonucleotide of the sequence without modification). In contrast, in the case of tBu1T, even after thermal cycling, no detachment of the protecting group was observed ( Fig.10 Therefore, the stability of Me and tBu type modifications was compared, and the results showed the superiority of the latter.

[0183] (3) Experiment showing stability (degradation resistance) of modified primers under PCR conditions (comparison of the number of tBu analogs introduced: 1, 2, and 3)

[0184] (Reaction Conditions)

[0185] A solution composed of 20 mM Tris-HCl solution containing 10 μM oligonucleotide (tBu1T, tBu2T or tBu3T), 10 mM (NH4)2SO4, 10 mM KCl, 2 mM MgSO4, pH 8.8 was heated under the following conditions [(95°C, 1 min → 50°C, 30 sec → 72°C, 3 min) × 30 cycles] and then analyzed by reverse phase HPLC.

[0186] (Analysis conditions)

[0187] System: LaChrom Elite manufactured by Hitachi High-Tech Science;

[0188] Chromatographic column: Hydrosphere C18 (250 × 4.6 mm) manufactured by YMC;

[0189] Mobile phase: Solution A: 50 mM triethylammonium acetate (TEAA, pH 7.0) containing 5% acetonitrile;

[0190] Solution B: acetonitrile;

[0191] (The content of liquid B was divided into 20 parts and increased from 0% to 60% (linear gradient));

[0192] Mobile phase flow rate: 1 mL / min;

[0193] Detection wavelength: 260nm.

[0194] (result)

[0195] like Fig.11As shown, even when the number of introduced modifications was increased to 2 or 3, no removal of the protecting group was observed under the conditions.

[0196] (4) Reverse-phase HPLC analysis of deprotection reaction of tBu-modified primers

[0197] (Deprotection reaction conditions)

[0198] light irradiation ( Fig.12 (b)): 10 μM oligonucleotide, 10 mM Tris-HCl (pH 8.5);

[0199] At 4mW / cm 2 The solution was irradiated with 365 nm light for 10 min;

[0200] Reduction reaction ( Fig.12 (c)): 5 μM oligonucleotide, 10 mM Na2S2O4, 20 mM Tris-HCl (pH 8.5);

[0201] The solution was incubated at 25°C for 30 minutes.

[0202] (Analysis conditions)

[0203] System: LaChrom Elite manufactured by Hitachi High-Tech Science;

[0204] Chromatographic column: Hydrosphere C18 (250 × 4.6 mm) manufactured by YMC;

[0205] Mobile phase: Solution A: 50 mM triethylammonium acetate (TEAA, pH 7.0) containing 5% acetonitrile;

[0206] Solution B: acetonitrile;

[0207] (The content of liquid B was divided into 20 parts and increased from 0% to 60% (linear gradient));

[0208] Mobile phase flow rate: 1 mL / min;

[0209] Detection wavelength: 260nm.

[0210] It has been confirmed that deprotection is possible even under the following reducing conditions.

[0211] 10 μM oligonucleotide, 10 mM B2(OH)4, 50 mM NaOH, 30% EtOH / water; 25°C, 2 hours;

[0212] 10 μM oligonucleotide, 1.5 mM TiCl3, 20 mM citrate buffer (pH 6.0); 25°C, 2 hours;

[0213] like Fig.12 As shown, quantitative reactions were confirmed in both the 365 nm light irradiation and the reduction reaction with sodium dithionite.

[0214] (5) Ligation reaction of PCR products in a test tube (Taq DNA ligase)

[0215] use Fig.13 The double-stranded DNA fragment was prepared by PCR reaction using the thermostable polymerase described in. The template for preparing the 1.0 kb fragment was pET21 plasmid DNA, and the primer sequences were the following two sequences.

[0216] Underlined part T( T ) indicates that the phosphate moiety contains Me or tBu type modification groups. p indicates that the 5' end is phosphorylated.

[0217] Fw(21-nt):5'CGCCGAGACAGAACTTAATGG 3';

[0218] Rev(38-nt):5'pAATCTCCTTCT TT AAGTTAAACAAAATTATTTCTAGAG 3';

[0219] The template used to prepare the 0.74 kb fragment was pAcGFP1 plasmid DNA, and the primer sequences were the following two sequences.

[0220] Underlined part T( T ) indicates that the phosphate moiety contains Me or tBu type modification groups. p indicates that the 5' end is phosphorylated.

[0221] Fw(35-nt): 5'pAAAGAAGGAGA TT AACCATGGTGAGCAAGGGCGCC 3′;

[0222] Rev(34-nt): 5'GCAACCAAGCTTCTCACTTGTACAGCTCATCCAT 3'.

[0223] Using the commercially available heat-resistant polymerase described in the figure, PCR reaction was carried out according to the recommended conditions to prepare a 1.0 kb fragment and a 0.74 kb fragment, respectively. The progress of the reaction was confirmed by agarose gel electrophoresis (1.5% Agarose S (Wako Pure Chemical Industries) containing GelRed (Wako Pure Chemical Industries)). After the PCR reaction, 200 μL of an equal amount of a mixture of TE saturated phenol (Nacalai Tesque) and chloroform was added to 200 μL of the reaction solution, and the mixture was vigorously mixed and centrifuged (20,000 × g, 1 minute) to separate the aqueous layer. Similarly, the reaction solution was extracted with 200 μL of chloroform, and then 20 μL of 3M NaOAc (pH 5.2) and 220 μL of isopropanol were added. After cooling at -30°C for 1 hour, the DNA was recovered by centrifugation (20,000 × g, 20 minutes). The target DNA product was purified by agarose gel electrophoresis (1.5% Agarose S (Wako Pure Chemical Industries, Ltd.) containing GelRed (Wako Pure Chemical Industries, Ltd.)). DNA was extracted from the excised gel slice using Wizard SV Gel and PCR Cleanup System (Promega).

[0224] The 1.0 kb fragment and the 0.74 kb fragment prepared in this way were ligated with Taq DNA ligase, and the efficiency was evaluated by agarose gel electrophoresis. 2The DNA solution (5 μL; 24 nM 1.0 kb fragment, 24 nM 0.74 kb fragment, 1 mM Tris-HCl (pH 8.5)) was irradiated with 365-nm light for 5 minutes. Then, Taq DNA ligase (New England Biolabs) was added to the solution containing the two DNA fragments and incubated at 37°C for 2 hours. The reaction solution composition is as follows: 2.8 nM 1.0 kb fragment, 2.8 nM 0.74 kb fragment, 1.6 U / μL Taq DNA ligase, 20 mM Tris-HCl, 25 mM potassium acetate, 10 mM magnesium acetate, 1 mM NAD 1, 10 mM DTT, 0.1% Triton X-100, pH 7.6. 80 μL of water was added to the reaction solution to make the total volume about 100 μL, and 100 μL of an equal amount of a mixture of TE saturated phenol (NacalaiTesque) and chloroform was added. After vigorous mixing, the mixture was centrifuged (20,000×g, 1 minute) to separate the aqueous layer. Similarly, the reaction solution was extracted with 100 μL of chloroform, and then 10 μL of 3M NaOAc (pH 5.2) and 110 μL of isopropanol and 1 μL of 20 mg / mL glycogen were added. After cooling at -30°C for 15 minutes, the mixture was centrifuged (20,000×g, 20 minutes) to recover the DNA. The recovered DNA product was electrophoresed by agarose gel electrophoresis (1.5% Agarose S (Wako Pure Chemical Industries)). The gel after electrophoresis was stained with GelRed aqueous solution to visualize the bands (BioRad ChemiDoc XRS+ system).

[0225] As shown in the figure, when the Me and tBu primers were compared, it was confirmed that a higher ligation efficiency was obtained with the latter.

[0226] (6) Replication reaction using oligonucleotide containing chain extension termination cage analog as template

[0227] The replication reaction experiment was carried out in the same manner as in the above-mentioned "(2) Replication reaction using an oligonucleotide containing a chain extension termination cage analog T* as a template".

[0228] The reaction solution for the enzyme reaction [containing 1 μM primer (5' fluorescein - ACCGAGCTCGAATTCGCC 3'), 1 μM template (sequence and structure described in each figure), 0.2 mM dNTPs, 0.02 units / μL polymerase] was prepared according to the recommended conditions using the buffer provided with each enzyme. The reaction solution was heated at 95°C for 1 minute, 55°C for 30 seconds, and then 72°C for 30 minutes using an Applied Biosystems 2720 thermal cycler. 10 μL of 2× formamide loading solution was added to 10 μL of the heated reaction solution, and after heating at 90°C for 3 minutes, the solution was analyzed by 20% modified PAGE containing 7.5 M urea ( Figure 14 to Figure 17 ). Based on the fluorescence from the fluorescein group modified at the 5' end of the primer chain, the oligonucleotide chain contained in the gel after electrophoresis was detected using the ChemiDoc XRS+ imaging system.

Claims

1. A method of using a primer for amplification of double-stranded DNA, characterized in that: The primer has a structure represented by the following formula (1): Here, B represents a base, R2 represents hydrogen, and * refers to the bond with the sugar of the adjacent nucleotide; and R1 represents a photodegradable protecting group having a structure represented by the following formula (4A), Here, R3 represents an alkyl group having 1 to 20 carbon atoms; or R1 represents a 4-nitrobenzyl group represented by the following formula (3B): 。 2. The use according to claim 1, characterized in that: The R1 represents a photodegradable protecting group having a structure represented by the formula (4A), and the R3 is a tert-butyl group or an adamantyl group.

3. The use according to claim 1, characterized in that: The R1 represents a photodegradable protecting group having a structure represented by the formula (4A), and the R3 is a methyl group.

4. The use according to claim 1, characterized in that: Two or more structures represented by the formula (1) are continuous in the sequence.

5. A double-stranded DNA production device, which is a double-stranded DNA production device that uses primers to produce double-stranded DNA with sticky ends, characterized in that The primers include a forward primer and a reverse primer, both of which have the structure shown in the following formula (1): Here, B represents a base, R2 represents hydrogen, and * refers to the bond with the sugar of the adjacent nucleotide; and R1 represents a photodegradable protecting group having a structure represented by the following formula (4A), Here, R3 represents an alkyl group having 1 to 20 carbon atoms; or R1 represents a 4-nitrobenzyl group represented by the following formula (3B): The manufacturing device comprises: The forward primer is complementary to a portion of the antisense strand of the template DNA serving as a template; The reverse primer is complementary to a portion of the sequence of the sense strand of the template DNA; an amplification device, which performs multiple cycles of polymerase chain reaction (PCR) using the template DNA as a template to generate a forward side extension strand extended by the forward primer and a reverse side extension strand extended by the reverse primer, and anneals the forward side extension strand and the reverse side extension strand to generate a double-stranded DNA with a 3' end recess; as well as The deprotection device deprotects the R1.

6. A method for producing double-stranded DNA, which is a method for producing double-stranded DNA having cohesive ends using primers, characterized in that: The primer has a structure shown in the following formula (1): Here, B represents a base, R2 represents hydrogen, * refers to the bond with the sugar of the adjacent nucleotide, and R1 represents a photodegradable protecting group having a structure represented by the following formula (2A), wherein A1 represents an alkylene group having 1 to 3 carbon atoms, which may have a branched chain having 1 to 20 carbon atoms, and * represents a bond with oxygen (O) of phosphoric acid; or R1 represents a reducing agent-degradable protecting group represented by the following formula (2B): Wherein, A2 represents an alkylene group having 1 to 3 carbon atoms, which may have a branched chain having 1 to 20 carbon atoms, and * represents a bond with oxygen (O) of phosphoric acid; The manufacturing method comprises the following steps: A preparation step of preparing a forward primer and a reverse primer, wherein the forward primer is complementary to a portion of the sequence of the antisense strand of a template DNA serving as a template and has a structure represented by the formula (1), and the reverse primer is complementary to a portion of the sequence of the sense strand of the template DNA and has a structure represented by the formula (1); an amplification step, performing multiple cycles of polymerase chain reaction (PCR) using the template DNA as a template to generate a forward-side extension strand extended by the forward primer and a reverse-side extension strand extended by the reverse primer, and annealing the forward-side extension strand and the reverse-side extension strand to generate a double-stranded DNA with a 3'-end recess; and The deprotection step is to deprotect the R1.

7. The method for producing double-stranded DNA according to claim 6, characterized in that: The R1 is a photodegradable protecting group represented by the formula (2A), and the deprotection step is performed by irradiating light to deprotect the R1.

8. The method for producing double-stranded DNA according to claim 6, characterized in that: The R1 is a reducing agent-decomposable protecting group represented by the formula (2B), and the deprotection step is performed by deprotecting the R1 using a reducing agent.

9. The method for producing double-stranded DNA according to claim 6, characterized in that: The primer has two or more structures represented by the formula (1) in succession in its sequence.